Decentralized Clinical Trials (DCT) 3rd-Party Platform

Context:
- It can have specialized components for DCT Sub-Tasks.
- It can be supported by an AI-Supported DCT Platform (solving an AI-supported DCT task).
- …
Example(s):
Counter-Example(s):
- a Centralized CT Platform.
See: Centralized Clinical Trial Platform.

References

https://everestgrp.com/reportaction/EGR-2022-46-R-5610/Marketing
- Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, flexibility in operations, and improved data quality. Before the pandemic, although the technology and data to support DCTs existed, only a few pilots were conducted. Today, the pressing need for remote patient- and site-centric trials has increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate going forward, indicating that DCTs are here to stay. Additionally, technology advances, innovative business models, increased wearables support, US FDA’s push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape.
- In this report, we assess the capabilities of 24 DCT platform providers. The providers are positioned on Everest Group’s PEAK Matrix®, a composite index of a range of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other.